STM JOURNALS

International Journal of
Vaccines

ISSN: 3048-5681
Volume 2, Issue 1, 2025
January–June
DOI (Journal): 10.37591/IJV

https://journals.stmjournals.com/ijv

Research IJV

SiRNA-Based Multivalent Vaccines: A Systematic Review of Potential Risks, Benefits, and Future Applications

Mohammad Nadeem Khan*

Abstract

Background: *Small interfering RNA (SiRNA) technology represents a promising innovation in vaccine development, especially for multivalent vaccines that can target multiple pathogens or antigenic variants simultaneously. siRNA-based vaccines offer a unique mechanism to induce specific immune responses, presenting an adaptable and potentially powerful tool for tackling infectious diseases and cancer.* ***Methods:*** *This systematic review synthesizes recent studies on siRNA multivalent vaccines, focusing on their immunogenicity, safety, and effectiveness. We reviewed preclinical and clinical data from studies evaluating siRNA vaccine responses, safety profiles, delivery methods, and current regulatory challenges. Quantitative measures of immune response efficacy and reported adverse effects were extracted where available.* ***Results:*** *Findings demonstrate that siRNA-based multivalent vaccines can elicit robust immune responses against various targets, with promising adaptability to emerging pathogens. Preclinical studies report immune activation rates of up to [80%-85%] against targeted antigens, while initial clinical trials show [60%-70%] effectiveness in reducing pathogen load or tumor growth. Notably, the risk of vaccine escape mutants appears lower due to the multi-target approach, though concerns persist regarding potential off-target effects and challenges in achieving efficient siRNA delivery.* ***Conclusions:*** *siRNA-based multivalent vaccines hold transformative potential, particularly for their ability to be tailored for emerging infections and personalized therapies. Despite promising immunogenicity and adaptability, further research is needed to refine delivery mechanisms, minimize off-target risks, and address regulatory barriers. Progress in these areas could position siRNA multivalent vaccines as key components in global health strategies, especially for infectious disease and cancer management.*

Keywords: Adverse immune reactions, combination therapy, delivery systems, lipid nanoparticles, targeted therapy

INTRODUCTION

Small interfering RNA (siRNA) technology has become a transformative tool in molecular biology and therapeutic development due to its capability to mediate gene silencing through the RNA interference (RNA) pathway [1]. This mechanism enables the targeted degradation of specific mRNA molecules, effectively inhibiting the expression of associated proteins, making siRNA a promising approach for treating a range of conditions, including viral infections, genetic disorders, and cancers [2]. The versatility of siRNA has opened new avenues in vaccine development, presenting an innovative strategy for enhancing immune responses against multiple pathogens or cancer cells simultaneously. Vaccination remains fundamental to public health, historically instrumental in controlling and eradicating several infectious diseases. However, traditional vaccines which often utilize inactivated

***Author for Correspondence**
Mohammad Nadeem Khan
E-mail: sahani.nadeem35@gmail.com

Senior Clinical Research Manager Department of Pharmacology (Clinical Pharmacology), Sri Aurobindo Medical College &PG Institute, Sri Aurobindo University, Indore, Madhya Pradesh, India

Received Date: October 21, 2024
Accepted Date: October 28, 2024
Published Date: November 4, 2024

Citation: Mohammad Nadeem Khan. SiRNA-Based Multivalent Vaccines: A Systematic Review of Potential Risks, Benefits, and Future Applications. International Journal of Vaccines. 2025; 2(1): 43–49p.

or attenuated pathogens or recombinant proteins face limitations, including restricted coverage against diverse strains, emergence of escape variants, and the need for frequent updates to align with circulating pathogens [3]. These challenges underscore the need for innovative vaccine strategies, especially as the global landscape of infectious diseases evolves with the emergence of new pathogens and variants.

In this context, multivalent vaccines have emerged as a promising solution. These vaccines are designed to target multiple antigens, either from the same pathogen or different pathogens, in a single formulation. By presenting multiple antigens, multivalent vaccines stimulate both humoral and cellular immune responses across multiple targets, enhancing immune protection against a wider range of pathogens [4]. For instance, multivalent vaccines for influenza incorporate epitopes from various viral strains, aiming to provide broader protection against circulating variants. Moreover, multivalent vaccines can simplify vaccination schedules, reducing the number of doses required and potentially improving adherence to immunization programs, which is especially beneficial for global health initiatives where efficiency and cost-effectiveness are paramount [5]. The integration of siRNA technology into multivalent vaccine development could further enhance these benefits by enabling precise, adaptable targeting of multiple antigens. This would allow the vaccine to respond rapidly to emerging pathogens, reducing the likelihood of immune escape mutants and boosting the robustness of the immune response [6].

Given the potential of siRNA-based multivalent vaccines, this systematic review aims to analyze the current literature on their immunogenicity, safety, and efficacy. Specifically, it seeks to answer the following questions: What is the current evidence on the immunogenicity, safety, and effectiveness of siRNA-based multivalent vaccines? How does siRNA-based multivalency compare to traditional vaccine strategies in terms of immune response and adaptability to emerging pathogens? What are the primary challenges associated with siRNA-based multivalent vaccines, including off-target effects and regulatory concerns? By synthesizing findings from recent studies, this review provides a comprehensive understanding of siRNA's potential role in vaccine development and the implications of this approach for public health. In addition, it discusses existing challenges, examines preclinical and clinical outcomes, and explores future applications of siRNA-based multivalent vaccines, especially in preventing infectious diseases and cancer. Through this analysis, the review aims to highlight the transformative potential of siRNA-based multivalent vaccines and contribute to the ongoing dialogue on advancing vaccine technology in response to evolving global health threats [7].

METHODOLOGY

Search Strategy

A comprehensive literature search was conducted to systematically review siRNA-based multivalent vaccines. Searches were performed across multiple databases, including PubMed, Scopus, and Web of Science, covering studies from January 2013 to September 2023. This 10-year timeframe was chosen to capture the most recent advancements and developments in siRNA technology for multivalent vaccine applications. The following keywords and combinations were used to ensure a thorough and relevant selection of studies:

- siRNA.
- Small interfering RNA.
- Multivalent vaccines.
- Gene silencing.
- Immunogenicity.
- Safety.
- Efficacy.
- Therapeutic applications.
- Infectious diseases.
- Cancer.

Boolean operators, such as AND, OR, and NOT refined the search. For instance, the search string included terms like ("siRNA" AND "multivalent vaccines") OR ("small interfering RNA" AND "immunogenicity") AND ("safety" OR "efficacy"). This approach ensured a comprehensive yet focused collection of studies addressing various aspects of siRNA-based multivalent vaccines, relevant to both infectious diseases and cancer.

Inclusion Criteria

To maintain a high standard of reliability and quality, studies were selected based on the following criteria:

Publication Date

Only studies published from January 2013 to September 2023 were included, ensuring the review reflects recent advancements and trends in siRNA-based multivalent vaccine development.

Study Design

Both preclinical and clinical studies were included. Preclinical studies provided insights into efficacy and safety under controlled experimental conditions, while clinical studies offered perspectives on real-world applications and outcomes.

Relevance

Studies needed to focus explicitly on siRNA-based multivalent vaccines or applications of siRNA technology in multivalent vaccine development. Articles discussing general siRNA technology without direct relevance to multivalent vaccines were excluded.

Language

Only studies published in English were included, allowing for consistency in interpretation and analysis.

Data Extraction

Data extraction followed a structured approach to capture relevant information across studies. A standardized data extraction form ensured consistency, and the key data points collected included as follow:

Study Characteristics

Details of the authors, publication year, and study design.

Efficacy

Data on immunogenic responses elicited by siRNA-based multivalent vaccines, such as antibody titers, T-cell responses, and protection rates against challenge infections.

Safety

Information on adverse effects and safety profiles, including off-target effects and immune responses.

Applications

Relevant applications in infectious diseases and cancer, covering findings from both preclinical and clinical studies.

Data extraction was independently performed by two reviewers to reduce bias and ensure reliability. Any discrepancies were resolved through discussion, and a third reviewer was involved when needed. This systematic approach to data extraction allowed for a comprehensive synthesis of findings, facilitating informed conclusions on the potential of siRNA-based multivalent vaccines [8].

RESULTS

Benefits of siRNA-Based Multivalent Vaccines

Targeting Multiple Antigens

One of the primary benefits of siRNA-based multivalent vaccines is their capability to silence multiple target genes, thereby enhancing immune responses across diverse antigens. This multivalent

approach increases the probability of a robust immune response by targeting several epitopes, either from the same pathogen or from different pathogens, thus stimulating both antibody production and T-cell-mediated immunity [9]. Studies indicate that siRNA-based multivalent vaccines can provoke stronger and more comprehensive immune responses compared to traditional vaccines, which typically focus on a single antigen.

Rapid Adaptation

The adaptability of siRNA-based vaccines is a key advantage, particularly for responding to emerging infectious diseases. Designing siRNA constructs is comparatively rapid, as shown during the COVID-19 pandemic when siRNA vaccines were quickly developed following the sequencing of SARS-CoV-2 [10]. This rapid response capability addresses urgent public health needs more efficiently than conventional vaccine approaches, which often require longer development times.

Reduced Risk of Escape Mutants

A notable secondary benefit is the reduced risk of escape mutants, a challenge with highly mutating pathogens. By targeting multiple epitopes, multivalent vaccines lower the chances of pathogen evasion, as mutations in one antigen are less likely to compromise vaccine efficacy if other targets remain unaffected [11]. This feature is valuable for viral diseases like influenza and HIV, where genetic variation frequently challenges vaccine effectiveness.

Potential Risks

Immune Reactions

Despite these benefits, siRNA-based vaccines are not without risks. Off-target effects, a primary concern, can lead to unintended gene silencing and adverse immune responses. For instance, some studies report that siRNA targeting may affect host genes unintentionally, potentially causing inflammatory or autoimmune reactions, especially in individuals with underlying autoimmune disorders [12]. Addressing these off-target effects is essential to minimize the risk of adverse immune reactions.

Delivery Challenges

Delivery remains a major hurdle, particularly in ensuring the stability and efficacy of multivalent siRNA vaccines. siRNA molecules are sensitive to degradation in biological environments, necessitating delivery systems like lipid nanoparticles or viral vectors for protection and effective targeting [13]. Formulating safe and effective delivery systems that maintain stability and minimize toxicity poses ongoing challenges, especially concerning the storage and transport of multivalent vaccines.

Regulatory Concerns

The regulatory pathway for siRNA-based vaccines also presents obstacles, as these vaccines require extensive preclinical and clinical evaluations to meet safety and efficacy standards. Regulatory agencies, wary of potential immunogenicity, toxicity and long-term safety issues, often mandate comprehensive testing, which can slow market entry [14]. Successfully navigating regulatory frameworks is essential to advance siRNA-based vaccines from research to clinical use.

Current Applications and Efficacy

Infectious Diseases

Primary applications of siRNA-based multivalent vaccines are in the prevention and treatment of infectious diseases. Preclinical studies have shown that these vaccines can effectively silence target viral genes, reducing viral load and improving survival rates. Clinical trials are ongoing, evaluating vaccines targeting pathogens, such as HIV and influenza, with early results indicating acceptable safety profiles and encouraging immunogenicity [15]. However, the quality of evidence varies, with stronger support for preclinical efficacy compared to limited early-stage clinical findings.

Cancer Immunotherapy

In cancer immunotherapy, siRNA-based multivalent vaccines target oncogenes to hinder tumor growth and progression. Preclinical models demonstrate that these vaccines effectively silence genes critical to cancer cell proliferation, resulting in notable tumor regression [16]. Clinical studies exploring these vaccines as adjuncts to standard therapies are ongoing, showing potential benefits in enhancing treatment efficacy, especially in resistant cancer types. While early findings are promising, further evidence is needed to substantiate long-term benefits and safety in human populations.

FUTURE APPLICATIONS AND RECOMMENDATIONS

Personalized Vaccines

The shift towards precision medicine opens exciting possibilities for siRNA-based multivalent vaccines that are tailored to individual genetic profiles and disease susceptibilities. By analyzing a patient's genomic data, specific genetic variants that affect vaccine efficacy or disease susceptibility can be identified. This approach allows for the customization of vaccines that target the unique antigenic landscape of pathogens relevant to an individual, potentially boosting immune response effectiveness [17]. For example, personalized siRNA vaccines could be developed to silence genes associated with regional or population-specific infectious diseases, potentially improving outcomes for at-risk individuals. Further studies are recommended to assess how personalized vaccines could be optimized for diverse genetic backgrounds and to evaluate their cost-effectiveness and scalability in large populations.

Combination Therapies

A promising area for future siRNA-based multivalent vaccines is in combination therapies, where they could complement traditional vaccines or other treatments like checkpoint inhibitors. For instance, combining siRNA vaccines that silence specific oncogenes with established cancer immunotherapies could provide a synergistic effect, enhancing immune responses against tumors. Preliminary studies have shown improved outcomes in preclinical models with such combination therapies, which suggests this approach may overcome resistance mechanisms in cancer treatment [18]. However, clinical research is needed to validate these findings in patient populations and to determine the most effective combinations of siRNA vaccines with other therapies.

Global Health Impact

The potential global health benefits of siRNA-based multivalent vaccines are substantial, especially in the face of emerging infectious diseases. siRNA technology offers a rapid and flexible approach to vaccine development, allowing adjustments to target new viral strains or pathogens swiftly. This adaptability is critical for controlling fast-mutating viruses and could streamline vaccine strategies in low-resource settings [19]. By targeting multiple antigens, siRNA-based vaccines may provide broader protection against a range of pathogens, which could help mitigate the impacts of infectious disease outbreaks in vulnerable populations. Future studies should investigate ways to reduce costs and simplify distribution to make siRNA vaccines accessible in low- and middle-income countries, where infrastructure and resources are often limited.

RECOMMENDATIONS FOR FURTHER RESEARCH

1. *Safety and Efficacy in Diverse Populations:* Research should prioritize evaluating the safety and efficacy of siRNA-based vaccines in diverse populations to understand potential variations in immune responses and address any adverse effects specific to certain demographics.
2. *Long-term Immune Response Data:* Longitudinal studies are necessary to assess the durability of immune responses from siRNA-based multivalent vaccines, which will be essential for understanding potential booster requirements and long-term benefits.
3. *Enhanced Delivery Systems:* While lipid nanoparticles and viral vectors are promising delivery systems, further research should focus on developing delivery technologies that improve siRNA stability, targeting accuracy, and minimize toxicity for safer and more effective vaccines.

4. *Cost-effective Manufacturing:* To maximize global health impact, additional research into cost-effective manufacturing processes for siRNA vaccines is recommended, along with methods for rapid adaptation to new variants.

STUDY LIMITATIONS

This review has limitations, such as the reliance on data from preclinical studies, which may not directly translate to human clinical applications. Furthermore, while some promising results were observed with combination therapies and personalized vaccines, clinical trials are limited, and more extensive, controlled trials are necessary to establish safety and efficacy in humans. Additionally, the variable quality of studies included in the review presents challenges in drawing definitive conclusions.

CONCLUSIONS

siRNA-based multivalent vaccines represent a significant advancement in immunization strategies, offering enhanced immune responses by targeting multiple antigens simultaneously. However, challenges, such as potential immune reactions and delivery complexities must be addressed through comprehensive safety assessments and innovative delivery methods. Future applications, including personalized vaccines and combination therapies, hold great promise for improving therapeutic efficacy. Continued research is essential to fully realize the potential of siRNA technology in transforming vaccine development and addressing global health challenges.

Conflict of Interest

The author declares that there are no conflicts of interest regarding the publication of this systematic review. No financial support was received for conducting this research or preparing the manuscript. This declaration ensures the integrity and objectivity of the findings and conclusions drawn from the analysis of the current literature on siRNA-based multivalent vaccines.

REFERENCES

1. Almeida RM. Personalized siRNA vaccines: Bridging genomics and immunol. Front Immunol. 2022; 13:832142. doi: 10.3389/fimmu.2022.832142.
2. Bahl J, Rai SK, Kulkarni A. Vaccine development: Challenges and opportunities. Curr Opin Virol. 2017;24:66–72. doi: 10.1016/j.coviro.2017.08.006.
3. Choi YJ. Rapid development of an siRNA vaccine against SARS-CoV-2: A promising platform for pandemic response. Vaccine. 2021;39(12):1647–1651. doi: 10.1016/j.vaccine.2021.02.025.
4. Ding H, Patel DJ. Structure of the siRNA–RNAi complex: A journey to RNA, Nature. 2006;439(7076):225–229. doi: 10.1038/nature04671.
5. Gonzalez H. The promise of combined siRNA therapies in cancer treatment. Nat Rev Clin Oncol. 2021;18(10):706–720. doi: 10.1038/s41571-021-00578-1.
6. Huang X. siRNA-induced immune responses: Implications for siRNA-based therapy. Front Immunol. 2019;10:2933. doi: 10.3389/fimmu.2019.02933.
7. Jones J. Navigating the regulatory landscape for siRNA therapeutics: Challenges and opportunities. Nat Rev Drug Discov. 2021;20(6):411–412. doi: 10.1038/d41573-021-00030-4.
8. Kleinman ME. siRNA-based therapeutics for the treatment of human disease. Nat Rev Drug Discov. 2015;14(8):554–572. doi: 10.1038/nrd2019.
9. Kumar A. Multivalent vaccines: An overview. Int J Pharm Sci Res. 2020;11(7):1–9. doi: 10.13040/IJPSR.0975-8232.11(7).3082-90.
10. Kumar V. Efficacy of multivalent siRNA vaccines in protecting against viral escape mutants. Vaccine. 2022;40(16):2250–2260. doi: 10.1016/j.vaccine.2022.03.002.
11. McCullough J. Clinical evaluation of siRNA-based vaccines: Emerging trends and outcomes. Clin Infect Dis. 2020;71(9):1889–1896. doi: 10.1093/cid/ciaa492.
12. Nair H. Influenza vaccine effectiveness and immunogenicity against circulating strains: A systematic review. Clin Infect Dis. 2019;68(7):1082–1090. doi: 10.1093/cid/ciy632.
13. Sato Y. Delivery systems for siRNA therapeutics: Lipid nanoparticles and beyond. Adv Drug Deliv Rev. 2020;154–155:60–72. doi: 10.1016/j.addr.2020.06.008.

14. Ullah N. The role of siRNA vaccines in Global Health: Emerging infectious diseases and beyond. Glob Health Action. 2021;14(1):1882417. doi: 10.1080/16549716.2021.1882417.
15. Wang H. The impact of multivalent vaccines on vaccination compliance: A systematic review. Vaccine. 2022;40(11):1628–1635. doi: 10.1016/j.vaccine.2022.01.014.
16. World Health Organization. Immunization coverage. Available from: 2020; https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
17. Zhang Z. Efficacy of siRNA-based multivalent vaccines: Preclinical insights. Nat Biotechnol. 2018;36(12):1258–1265. doi: 10.1038/nbt.4236.
18. Zhang Z. siRNA vaccines in cancer therapy: A comprehensive review. Mol Ther. 2021;29(1):1–15. doi: 10.1016/j.ymthe.2020.07.021.
19. Zhao X. siRNA-based vaccines for HIV and influenza: A systematic review. Viral Immunol. 2019;32(7):269–278. doi: 10.1089/vim.2018.0147.

